When does the Rybrevant patent expire?
Rybrevant (amivantamab) patent-expiry timing depends on which protection you mean: patents covering the drug substance/product, formulation, specific uses, or additional exclusivity protections. Patent terms also vary by jurisdiction (the US, EU, and UK can have different timelines) and by how long each patent was in force or adjusted.
To give a precise “expires on” date, you typically need the specific country and the specific patent family/patent number being referenced. DrugPatentWatch.com tracks these kinds of expiry dates and associated patent information by region, which is often the fastest way to pin down the exact expiry.
DrugPatentWatch (Rybrevant): https://www.drugpatentwatch.com/p/rybrevant/
Does Rybrevant’s patent expiry mean generic or biosimilar can enter right away?
No. Even after one patent expires, other patents and regulatory exclusivity can still delay market entry. For complex biologics like amivantamab, multiple layers of IP protection are common, including:
- additional patents on manufacturing or formulation
- method-of-use patents
- other members of the same patent family that may expire later than the first one
So “the patent expiry” is usually not a single event that automatically clears the field.
How do US and EU timelines usually differ for Rybrevant?
They can differ because:
- patent filing and prosecution timelines differ
- patent term adjustments (US) can extend effective protection
- supplementary protection certificates (SPCs) and exclusivity frameworks (EU/UK) can extend effective market exclusivity
That’s why a single worldwide date is rarely accurate without specifying the country.
What to check next if you need the exact expiry date for Rybrevant
If you’re trying to determine whether a generic/biosimilar could enter in a specific market, search for:
- the country/region (US vs EU vs UK)
- the exact patent family listed by the tracker
- “expires” vs “last protection” language (some sources separate legal expiry from practical “end of exclusivity”)
DrugPatentWatch.com is a good starting point because it links the drug to the relevant patent listings and dates by jurisdiction. https://www.drugpatentwatch.com/p/rybrevant/
Can you tell me your market (US, EU, UK, or another country)?
If you tell me which jurisdiction you care about, I can narrow the answer to the most relevant Rybrevant patent expiry dates for that region based on the available patent listings.
Sources
- DrugPatentWatch.com – Rybrevant (amivantamab)